UroGen Pharma’s (URGN) “Buy” Rating Reiterated at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital’s price target indicates a potential upside of 166.81% from the company’s current price.

A number of other research firms have also recently commented on URGN. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $64.00 target price on shares of UroGen Pharma in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $40.00.

UroGen Pharma Stock Down 4.6 %

Shares of URGN stock traded down $0.45 during mid-day trading on Monday, hitting $9.37. 104,375 shares of the stock traded hands, compared to its average volume of 364,119. The stock’s fifty day moving average is $10.45 and its two-hundred day moving average is $11.76. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma has a 52-week low of $9.03 and a 52-week high of $20.70. The stock has a market cap of $219.76 million, a P/E ratio of -2.96 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Equities analysts predict that UroGen Pharma will post -3.12 EPS for the current year.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

Several institutional investors have recently added to or reduced their stakes in the stock. Toronto Dominion Bank acquired a new position in UroGen Pharma during the fourth quarter worth $18,628,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in UroGen Pharma by 2.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock valued at $14,667,000 after acquiring an additional 36,084 shares during the period. Vestal Point Capital LP boosted its holdings in UroGen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock valued at $17,360,000 after acquiring an additional 1,230,000 shares during the period. Stonepine Capital Management LLC grew its position in UroGen Pharma by 15.7% in the 4th quarter. Stonepine Capital Management LLC now owns 324,324 shares of the company’s stock valued at $3,454,000 after acquiring an additional 43,979 shares in the last quarter. Finally, RTW Investments LP lifted its position in shares of UroGen Pharma by 1.3% during the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock worth $40,841,000 after purchasing an additional 47,447 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.